VERV241220C12500
- 0.05
- 0.000.00%
Verve Therapeutics Newsroom
Express News | Bvf Partners LP Reports 8.2% Passive Stake in Verve Therapeutics Inc as of Nov 11 - SEC Filing
ARKK's Holdings Ranked by SA Quant Grades
CRISPR, Beam, Other Gene Editing Names up Significantly
RBC Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Cuts Target Price to $17
J.P. Morgan Maintains Verve Therapeutics(VERV.US) With Hold Rating, Cuts Target Price to $23
CCORF Maintains Verve Therapeutics(VERV.US) With Buy Rating, Raises Target Price to $32
RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating
Verve Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Verve Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Verve Therapeutics(VERV.US), With a Forecast Between $14 to $23
Positive Outlook on Verve Therapeutics: Promising VERVE-102 Trial Results and Genetic Editing Advancements
Verve Therapeutics Price Target Lowered to $14 From $15 at H.C. Wainwright
Express News | Verve Therapeutics Inc : Canaccord Genuity Raises Target Price to $32 From $29
Verve Therapeutics | 10-Q: Q3 2024 Earnings Report
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates
Verve Therapeutics | 8-K: Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
Express News | Verve Therapeutics: Expects Capital Position to Be Sufficient to Fund Its Operations Through 2026
Verve Therapeutics Has Cash, Cash Equivalents, and Marketable Securities of $539.9 M >VERV
Express News | Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
Express News | Verve Therapeutics Q3 Net Income USD -50.133 Million